Why It Matters
National Surgical Adjuvant Breast and Bowel Project registered as a new client with Saxton & Stump LLC on August 1st. National Institutes of Health (NIH) grant terminations disrupted 383 active clinical trials affecting more than 74,000 enrolled participants. Congressional members have shown sustained interest in the organization, with 25 communications referencing it in recent months split between House and Senate
Broader Context
The organization’s entry into lobbying comes as the federal government has slashed cancer research funding. The White House proposed cutting the National Cancer Institute’s budget by approximately 37 percent for fiscal year 2026, from $7.22 billion to roughly $4.53 billion. The federal government cut approximately $2.7 billion in NIH funding over the first three months of 2025, with a 31 percent decrease in cancer research funding during that same period. NIH grant terminations disrupted 383 active clinical trials affecting more than 74,000 enrolled participants. The National Cancer Institute also eliminated funding for the Pediatric Brain Tumor Consortium, “ending its support for a 26-year-old push to advance clinical trials for children with brain tumors.”
Bottom Line
The National Surgical Adjuvant Breast and Bowel Project’s lobbying registration represents a research organization responding to budget pressures that have disrupted hundreds of active medical trials. With no expenses reported and no specific legislative targets listed, the filing suggests an early-stage engagement
Access the Legis1 platform for comprehensive political news, data, and insights
Spot something wrong? Report an issue with this article
